Serious Infection Rates Among Patients with Select Autoimmune Conditions: A Claims-Based Retrospective Cohort Study from Taiwan and the USA

George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. Ann Intern Med. 2020;173(11):870–8.

Article  Google Scholar 

Jung JY, Yoon D, Choi Y, Kim HA, Suh CH. Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Sci Rep. 2019;9(1):9704.

Article  Google Scholar 

Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–65.

Article  Google Scholar 

Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137.

Article  Google Scholar 

Sathish JG, Sethu S, Bielsky MC, et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov. 2013;12(4):306–24.

Article  CAS  Google Scholar 

Feldman CH, Hiraki LT, Winkelmayer WC, et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2015;67(6):1577–85.

Article  Google Scholar 

Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 2009;18(8):682–9.

Article  CAS  Google Scholar 

Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Curr Opin Rheumatol. 2017;29(4):323–30.

Article  CAS  Google Scholar 

Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39(9):1475–82.

Article  CAS  Google Scholar 

Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26(5):663–70.

Article  Google Scholar 

Teh CL, Wan SA, Ling GR. Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. Clin Rheumatol. 2018;37(8):2081–6.

Article  CAS  Google Scholar 

Subesinghe S, Rutherford AI, Byng-Maddick R, Leanne Hyrich K, Benjamin GJ. Recurrent serious infections in patients with rheumatoid arthritis—results from the british society for rheumatology biologics register. Rheumatol (Oxford). 2018;57(4):651–5.

Article  Google Scholar 

Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785–91.

Article  Google Scholar 

Thong KM, Chan TM. Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis. Lupus. 2019;28(3):334–46.

Article  CAS  Google Scholar 

Zhang CX, Cai L, Zhou ZY, et al. Clinical manifestations, immunological features and prognosis of Chinese pediatric systemic lupus erythematosus: a single-center study. Int J Rheum Dis. 2019;22(6):1070–6.

CAS  Google Scholar 

Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019;78(4):456–64.

Article  CAS  Google Scholar 

Nguyen-Khoa BA, Goehring EL Jr, Alexander KA, Dong W, Napalkov P, Jones JK. Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-alpha drugs. Semin Arthritis Rheum. 2012;42(2):119–26.

Article  CAS  Google Scholar 

Li YC, Huang J, Li X, Zhao SM. A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis. Nefrologia. 2019;39(3):269–76.

Article  Google Scholar 

Kim Y, Yoon HE, Chung BH, et al. Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy. Korean J Intern Med. 2019;34(5):1091–9.

Article  CAS  Google Scholar 

Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14(12):1043–53.

Article  CAS  Google Scholar 

Kelly C, Hamilton J. What kills patients with rheumatoid arthritis? Rheumatology (Oxford). 2007;46(2):183–4.

Article  CAS  Google Scholar 

Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1):e000935.

Article  Google Scholar 

Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatol (Oxford). 2013;52(1):53–61.

Article  CAS  Google Scholar 

Kidney Disease Improving Global Outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;(3):1–150.

van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol. 2014;25(1):150–8.

Article  Google Scholar 

Tien YC, Yen HH, Chiu YM. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(5):831–6.

Google Scholar 

Lin CT, Huang WN, Hsieh CW, et al. Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis—a three-year study in Taiwan. J Microbiol Immunol Infect. 2019;52(1):141–50.

Article  CAS  Google Scholar 

Kurts C, Panzer U, Anders HJ, Rees AJ. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol. 2013;13(10):738–53.

Article  CAS  Google Scholar 

Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179–99.

Article  CAS  Google Scholar 

Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22(8):1361–70.

CAS  Google Scholar 

Keebler D, Teng E, Chia J, Galanter J, Peake J, Tuckwell K. Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials. Rheumatol (Oxford). 2020;59(10):3023–31.

Article  Google Scholar 

Hsieh CY, Su CC, Shao SC, et al. Taiwan’s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349–58.

Article  Google Scholar 

Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.

Article  Google Scholar 

Breslow NE, Day NE. Indirect standardization and multiplicative models for rates, with reference to the age adjustment of cancer incidence and relative frequency data. J Chronic Dis. 1975;28(5–6):289–303.

Article  CAS  Google Scholar 

Bains N. Standardization of rates. Association of Public Health Epidemiologists in Ontario; Ontario, Canada; 2009. http://core.apheo.ca/resources/indicators/Standardization%20report_NamBains_FINALMarch16.pdf. Accessed 1 Nov, 2022.

Lim CC, Liu PY, Tan HZ, et al. Severe infections in patients with lupus nephritis treated with immunosuppressants: a retrospective cohort study. Nephrol (Carlton). 2017;22(6):478–84.

Article  CAS  Google Scholar 

Battaglia M, Garrett-Sinha LA. Bacterial infections in lupus: roles in promoting immune activation and in pathogenesis of the disease. J Transl Autoimmun. 2021;4:100078.

Article  CAS  Google Scholar 

Caporali R, Caprioli M, Bobbio-Pallavicini F, Montecucco C. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8(2):139–43.

Article  CAS  Google Scholar 

Pego-Reigosa JM, Nicholson L, Pooley N, et al. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. Rheumatol (Oxford). 2021;60(1):60–72.

Article  Google Scholar 

Luijten RK, Cuppen BV, Bijlsma JW, Derksen RH. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus. 2014;23(14):1512–6.

Article  CAS  Google Scholar 

Tektonidou MG, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996–2011. Arthritis Care Res (Hoboken). 2015;67(8):1078–85.

Article  Google Scholar 

Jinno S, Lu N, Jafarzadeh SR, Dubreuil M. Trends in hospitalizations for serious infections in patients with rheumatoid arthritis in the US between 1993 and 2013. Arthritis Care Res (Hoboken). 2018;70(4):652–8.

Article  Google Scholar 

Herrinton LJ, Liu L, Goldfien R, Michaels MA, Tran TN. Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials. J Rheumatol. 2016;43(8):1503–9.

Article  Google Scholar 

Simard JF, Rossides M, Gunnarsson I, Svenungsson E, Arkema EV. Infection hospitalisation in systemic lupus in Sweden. Lupus Sci Med. 2021;8(1):e000510.

Article  Google Scholar 

Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.

Article  CAS  Google Scholar 

Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.

Article  Google Scholar 

Hsieh CR, Liu YM. Availability, health-care costs, and utilization patterns of biologics in Taiwan. Value Health. 2012;15(1 Suppl):S35-42.

Article  Google Scholar 

Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159–68.

Article 

留言 (0)

沒有登入
gif